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SUMMARY Background
Proton pump inhibitors and laparoscopic anti-reflux surgery (LARS) offer longterm symptom control to patients with gastro-oesophageal reflux disease (GERD).
Aim
To evaluate the process of 'normalisation' of the squamous epithelium morphology of the distal oesophagus on these therapies.
Methods
In the LOTUS trial, 554 patients with chronic GERD were randomised to receive either esomeprazole (20-40 mg daily) or LARS. After 5 years, 372 patients remained in the study (esomeprazole, 192 ; LARS, 180). Biopsies were taken at the Z-line and 2 cm above, at baseline, 1, 3 and 5 years. A severity score was calculated based on: papillae elongation, basal cell hyperplasia, intercellular space dilatations and eosinophilic infiltration. The epithelial proliferative activity was assessed by Ki-67 immunohistochemistry.
INTRODUCTION
Gastro-oesophageal reflux disease (GERD) is a widespread chronic disorder, the incidence of which is increasing worldwide. 1 The primary goal of GERD treatment is symptom control, restoring health-related quality of life and reducing societal costs. [2] [3] [4] [5] [6] Despite the low prevalence of macroscopic lesions, the healing of these breaks is prioritised over symptom relief by many experts to prevent the development of complications such as strictures or Barrett's oesophagus. 7, 8 Endoscopic monitoring is not justified in routine clinical practice, with the exception of patients with severe oesophagitis, because the therapeutic relief of symptoms is predictive of endoscopic healing of mucosal breaks. [2] [3] [4] [5] [6] The correlation between endoscopic healing and symptom relief is, however, not perfect in individual patients.
Histological assessment of the distal oesophageal mucosal lining has been advocated using basal cell thickness, size of intercellular spaces and papillary length, because changes in these reportedly occur as a consequence of reflux-induced damage. [9] [10] [11] Previous work evaluating biopsy samples at 2 cm above the Z-line and at Zline for the same GERD-associated histological lesions used immunohistochemistry for T lymphocytes, B lymphocytes, NK cells, macrophages, mast cells and Langerhans cells. 12 It was found that only intraepithelial T lymphocytes correlated with the histological lesions both in reflux oesophagitis and non-erosive disease; the other cell types had a limited role in GERD. However, concern has been raised regarding the relevance of these morphological changes. [13] [14] [15] [16] Even if available morphological data on the squamous epithelium currently have little practical impact on the management of GERD, they may well influence our understanding of the pathogenesis of GERD and its chronic, progressive and relapsing nature. No data are available on the long-term outcome of microscopic mucosal lesions in patients treated with either proton pump inhibitors (PPIs) or laparoscopic anti-reflux surgery (LARS). Through a comparison of these different therapeutic methods, with the latter virtually eradicating all types of reflux and PPIs controlling only the acid component of the refluxate, [17] [18] [19] important new insights can be gained on the pathogenesis, perpetuation and control of GERD. The results of the randomised long-term study comparing LARS and maintenance PPI therapy (the LOTUS trial) have been extensively reported, 20, 21 and in addition to the primary aims, a histological monitoring protocol of the distal oesophagus was followed. The 3-year follow-up results revealed an expected rapid initial improvement from baseline levels of all histological parameters indicative of GERD, 22 but full 'normalisation' was not reached.
Here, we report the outcome of continued surveillance of the squamous oesophageal epithelium for up to 5 years in patients treated with LARS or PPI therapy. Several questions remained: Can the histological changes in the distal oesophagus be 'normalised' in a longer time frame? Can any variable predict the risk of clinical treatment failure and/or suboptimal control of GERD symptoms? Does the acidity of the refluxate affect the process of normalisation of the oesophageal mucosal lining? Does cell proliferation in the mucosa parallel the histological findings and, if so, is this the case along the axis of the distal oesophagus?
MATERIALS AND METHODS

Study design and endpoints
The primary objective of the LOTUS trial (NCT00251927 -Long-Term Usage of Esomeprazole vs. Surgery for Treatment of Chronic GERD) was to compare, in parallel, the efficacy of long-term medical treatment [esomeprazole (ESO) 20 mg daily, increased to 40 mg daily if needed] with that of standardised LARS in patients with chronic GERD, assessed through endoscopy, 24-h pH-metry and symptom response. 20, 23 Patients with a history of oesophageal, gastric or duodenal surgery, current or historical evidence of ZollingerEllison syndrome, primary oesophageal disorders, inflammatory bowel disease, dysplastic changes in a columnarlined oesophagus or any condition associated with abnormal absorption from the gastrointestinal tract were excluded from the study, as were patients with other significant concomitant disease.
The primary endpoint of the LOTUS trial was time to clinical treatment failure, defined as the need for change in treatment for control of reflux disease. 20 In the ESO arm, this was when the patient reported that their symptoms were not sufficiently controlled by an initial dose increase to 40 mg once daily for 8 weeks or by a further increase to 20 mg b.d. for 8 weeks. In the LARS arm, if patients reported insufficient symptom control and again backed up by the need for regular drug treatment (regular anti-secretory drugs to control GERD symptoms, i.e., ≥4 weeks), the patient was classified as a treatment failure. The patient was also classified as a treatment failure when there were post-operative complaints requiring medical action, intraoperative death and post-operative death within 30 days after surgery or dysphagia requiring further treatment, or any other requirement to reoperate for symptom control. In the case of functional oesophageal stenosis, one dilatation was allowed. Secondary endpoints included histopathological changes in the squamous epithelium of the oesophagus, both at the Z-line and 2 cm above the Z-line. All authors had access to the study data and reviewed and approved the final version of this manuscript.
Histological assessments
Endoscopy was performed at baseline and after 1, 3 and 5 years. The biopsies were taken at the 3 o'clock position: grasping the squamous-columnar junction and at 2 cm above. 22 If columnar-lined oesophagus was suspected, further biopsies were taken from the suspected area. Biopsies were adhered to cellulose acetate strips and fixed in 10% buffered formalin solution, before being dehydrated in alcohol, embedded in paraffin and stained with haematoxylin and eosin with the orientation of biopsies such that serial sections could be performed at a 90°angle towards the surface of the epithelium.
The following lesions of the squamous epithelium were assessed: basal cell hyperplasia (BCH), dilated intercellular spaces (DIS), papillary elongation (PE) and the presence of intraepithelial inflammation (eosinophils, neutrophils) and necrosis/erosion. BCH, DIS, PE and intraepithelial inflammation were scored semi-quantitatively based on their percentage evaluation vs. the whole epithelial thickness. 22 Histological assessments were performed independently by two expert gastrointestinal pathologists (LM and RF) and any discrepancy was discussed and a consensus reached. The pathologists were blinded concerning the stage of the examination (baseline vs. post-therapy) and therapy group. A combined histological severity score, ranging from 0 to 2, was developed to describe the overall severity of all lesion types and was calculated by taking the average score of all assessable lesions. A combined severity score lower than 0.5 (i.e. no more than one mild lesion) was used to define 'normal' oesophageal histology; this value was based on previous data showing that this is the optimal cut-off value for separating individual patients with GERD from healthy well-matched controls (while 0.25 was the mean combined severity score of a group of healthy controls). 24 The highest combined severity score (i.e. score 2) was assigned to cases in which granulation tissue, necrosis or intraepithelial neutrophils were found. Figure 1 (aÀf) and Figure 2 (aÀc) show micrographs of haematoxylin and eosin stained sections to illustrate the scores that we used for classifying basal cell thickening, papillary length and dilations of intercellular spaces. The criteria and cut-offs that we used for scoring the lesions are detailed in supplementary Table 1 .
Immunohistochemistry
Serial sections 4-5-lm thick from each biopsy block were processed for immunohistochemistry. 25 Colourimetric recognition of the Ki-67 immunoreactive nuclear areas allowed the immunostained areas to be expressed as a percentage of the whole analysed area. Three high power fields (409) with the most intense Ki-67 expression were chosen for each case, both in poorly and welloriented areas. A Ki-67 score was calculated for each biopsy as the mean percentage Ki-67 expression of the three different fields. Figure 2 (dÀf) shows micrographs of sections for proliferating epithelial cells stained with Ki-67 antibodies.
24-h pH-metry
Intraoesophageal 24-h pH-metry was performed at baseline, 6 months and 5 years. The details of the recordings and analyses have been published recently. 26 Statistical analysis A Wilcoxon signed-rank test was used to analyse changes within treatment groups from baseline to 1, 3 and 5 years for all individual variables except for the combined severity score, for which a one-sample t-test was used. A Wilcoxon two-sample test was used to analyse differences between treatments with regard to changes from baseline to 1, 3 and 5 years for all individual variables except for the combined severity score, for which a two-sample t-test was used. Pearson correlation coefficients were calculated to determine association between combined histological severity score and Ki-67 expression. A two-way analysis of variance was applied to assess the relationship between chronic inflammation and acid reflux; percentage of the total recording time with a pH lower than 4.0 was used as the response variable and presence or absence of inflammation and study treatment were used as factors. The pH variable was transformed with the square root function owing to the skewedness of the data.
RESULTS
Study population
In total, 554 patients were randomised: 288 to LARS, of whom 40 were not operated on and 266 to ESO. 20, 23 There were six treatment failures in the LARS group Aliment Pharmacol Ther 2017; 45: 1339-1349before 1 year, 17 between 1 year and 3 years and a further 10 by 5 years; the corresponding numbers of treatment failures in the ESO group were 12 before 1 year, four between 1 year and 3 years and a further three by 5 years. In total, assessable histological samples were obtained at 5 years from 158 to 180 patients in the LARS and ESO groups respectively.
Histological assessments
Biopsies from the squamous epithelium at the Z-line. At baseline, biopsies from the squamous epithelium at the Z-line generally showed more severe changes than at 2 cm above. A drastic reduction from baseline in the scores for BCH, PE, DIS and eosinophils was seen during the first year in both the LARS and ESO groups at the Z-line. Thereafter, a slow but steady reduction occurred towards 'normal' values in both treatment groups, which was reached by 5 years of treatment (P < 0.001 for change in BCH, PE, DIS and eosinophils scores from baseline to 5 years for both the LARS and ESO groups, with the exception of eosinophils in the LARS group, Figure 3a-d) . The same rapid decrease (i.e. improvement) was seen in the combined severity score (Figure 5a ) from baseline to 1 year; 'normal' values were first observed at 5 years (P < 0.001 for change from baseline to 1, 3 and 5 years for both the LARS and ESO groups). When these changes were compared between the treatment groups, a similar level of improvement was seen at 1 year and onwards; however, the severity scores of all lesions were slightly but significantly higher (i.e. worse) in the LARS group at both 3 and 5 years (P = 0.002).
Biopsies from 2 cm above the Z-line. At 2 cm above the Z-line there was a significant improvement in scores at 1 year (P < 0.001 in all comparisons), with no difference between treatment groups. These profiles improved further during the subsequent 4 years but this difference did not reach statistical significance (Figure 4a-d) .
The change in combined severity score at 2 cm above the Z-line from baseline to 1, 3 and 5 years followed the same pattern towards 'normalisation' (P < 0.001 in all comparisons; Figure 5b ).
Combined data from Z-line and 2 cm above the Z-line.
When findings from the Z-line and 2 cm above the Z-line were combined, the change in combined severity score from baseline to 1, 3 and 5 years confirmed the pattern towards 'normalisation' (P < 0.001 in all comparisons, Figure 5c ) and reached an overall score very close to that previously reported in healthy controls. 23 Baseline oesophageal histology was available for 33 treatment failures vs. 254 responders in the LARS group at 5 years, and 19 failures vs. 245 responders in the ESO group at 5 years. There was no marked difference in combined severity scores at baseline for all responders vs. all treatment failures ( Table 1) . As per the protocol, we did not get biopsies from each patient at the exact time point at which a treatment failure was clinically documented. When individual patients were considered, the proportion of responders who still exhibited severe lesions (average combined severity scores ≥1.0) decreased over the study course, while those exhibiting normal histology (average combined severity scores <0.50) increased over this time period; however, the majority of patients overall did not achieve the values reported in healthy controls before 5 years of treatment (Table 2) . On the one hand, a significant relationship was detected between the time spent with oesophageal pH lower than 4.0 (i.e. total reflux time) at 6 months and the presence or absence of inflammation at 3 years (P = 0.047). On the other hand, when the total reflux time was related to the presence of inflammation at 5 years, no such relationship was detected (P = 0.48).
Immunohistochemistry
We observed a close correlation between the combined histological severity scores and Ki-67 tissue expression at baseline and 5 years; correlation coefficients ranged from 0.66 to 0.77 (P < 0.0001 at all occasions). At baseline, ESO, esomeprazole; LARS, laparoscopic anti-reflux surgery.
Severity score is the average of the combined severity scores from the Z-line and 2 cm above.
Z-line biopsies showed a higher proliferative activity than those taken at 2 cm above the Z-line, with no difference between treatment groups. After initiation of therapy, the largest changes occurred during the first year. Complete 'normalisation' was, however, not reached until 5 years of therapy ( Figure 6 ). We found no significant difference in Ki-67 tissue expression between the treatment groups at any of the time points, nor did we find that the Ki-67 score at baseline predicted the risk for treatment failures either at the Z-line or at 2 cm above.
DISCUSSION
Both surgical and medical anti-reflux therapies stimulate significant recovery of microscopic lesions of the squamous epithelium of the lower oesophagus and gastro-oesophageal junction (GEJ). Here, we observed a greater severity of lesions (both individual lesion types and combined histological score) at baseline in biopsies from the Z-line compared with those taken from 2 cm above the Z-line, confirming previous findings indicating that the Z-line area is exposed to the greater challenge by refluxate. 22 Our data are in agreement with observations made using pH telemetric probes positioned close to, and at different distances above, the Z-line in both patients with reflux oesophagitis and with non-erosive reflux disease. 27 A novel finding of this study was the unexpectedly long duration of the healing process required for 'normalisation' of the squamous epithelium: 5 years of reflux control was necessary to complete the healing process in the majority of patients, irrespective of whether we measured BCH, PE, DIS or eosinophils combined severity score or Ki-67 expression levels. This is an important observation that is not easy to explain given that the oesophagus epithelium is thought to heal rapidly, 28 but our findings suggest that healing continues during the last 2 years of our 5-year study period. Although as we reported in our 3 year study, full elimination of gastro-oesophageal reflux is not required for resolution of oesophagitis even at the microscopic level. Admittedly, the term 'normalisation' can be questioned; however, we consider normality to be represented by similarity with corresponding biopsy sites in healthy controls. 23 It should be noted that a small group of patients in both treatment groups had severe microscopic oesophagitis remaining at 5 years despite symptom control, normal acid exposure and endoscopically nonvisible mucosal breaks. Are these microscopic lesions due to damage induced by ingested material or other components contained in the saliva/refluxate? In this context it may be relevant to mention the recent hypothesis that refluxed gastric juice might not damage the oesophagus directly but rather incites a cytokine-mediated inflammatory response that ultimately causes oesophageal damage. 28 In addition, research related to the pathogenesis of eosinophilic oesophagitis, for example, 29 suggests that epithelial damage outside of the traditional betterunderstood forms should be explored further. Studies using ambulatory duodenogastric reflux monitoring, combined ambulatory impedance and pH-metry in the oesophagus (usually at 5 cm above the GEJ) have shown that LARS significantly reduces bilirubin exposure and the total duration of acid and non-acid reflux, thereby presumably reducing exposure of the oesophagus to all components of the refluxate. 18, 19, 30, 31 Using the same impedance pH-metry techniques, it has been found that even high doses of PPIs cannot reduce the frequency or cumulative duration of gastro-oesophageal reflux episodes to the same extent and degree as LARS. [32] [33] [34] Prolonged exposure of the oesophagus to damaging refluxate could therefore potentially maintain an inflammatory process in patients treated with PPIs. Furthermore, 24-h pH-metry performed at 6 months and 5 years after randomisation as part of the LOTUS trial protocol has shown a near eradication of acid reflux in the LARS group, compared with a 'normalisation' in the ESO group. 26 Our findings indicate that cessation of all types of reflux is not required for resolution of oesophagitis, even at the microscopic level.
A further unexpected observation of ours was the slight retardation of the healing process at the Z-line at 3 and 5 years in the LARS group compared with the ESO group. This observation does not fully concur with previous post-operative pH-metry data captured at 5 cm above the lower oesophageal sphincter; 26 however, it probably relates to the position of the surgical fundic wrap, which is placed above the GEJ, allowing the Z-line to remain partly exposed to gastric juices. The clinical relevance of these findings remains unclear, especially because neither the histological findings nor Ki-67 expression in these regions of the oesophageal mucosa predicted or correlated with the subsequent long-term disease course on each respective therapy. The traditional view on the management of chronic GERD is that both endoscopic and symptomatic relapses occur promptly after cessation of medical therapy, a risk which is independent of the duration of maintenance treatment. 4, 7, 8 Based on current data, it can be hypothesised that more time may be required to regain the resistance of the distal oesophageal epithelium to resist the recrudescence of abnormal reflux better. For example, residual abnormal scoring of the markers (e.g. DIS, BCH, PE and eosinophils) may increase the risk of relapse on cessation of therapy, as has been reported in other gastrointestinal diseases such as Crohn's disease. [35] [36] [37] Accordingly, a similar hypothesis could be tested in clinical studies, in which the slopes of the relapse curves may be determined as a function of the initial length of PPI maintenance therapy and the degree of morphological 'normalisation' of the squamous epithelium (e.g. 1, 3 and 5 years). The deleterious effects of the refluxate on the cell kinetics of the squamous epithelium at the GEJ and in the distal oesophagus were addressed in the present study by evaluation of Ki-67 expression. Results were consistent with those of conventional histology investigations, showing that 'normalisation' of proliferation in the oesophageal mucosa was attained irrespective of whether acid exposure to the region was abolished or just 'normalised'. In addition, Ki-67 expression, either at the Z-line or more proximal in the oesophagus, could not predict the risk of treatment failure during the subsequent 5 years on respective therapies.
In conclusion, considerable time (5 years) is required before oesophageal squamous epithelium morphology and cell proliferation rates are 'normalised' in most patients with chronic GERD, despite endoscopic and symptom control. Moreover, the pace and dynamics of these processes are the same, irrespective of whether the allocated therapy is surgical or medical. Accordingly, the acid component of the refluxate seems to be the pivotal component for the restoration of tissue morphology and epithelial cell proliferation rates.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article: Table S1 . Criteria used for scoring lesions. ESO, esomeprazole; LARS, laparoscopic anti-reflux surgery.
Lesion severity based on the average combined severity scores from the Z-line and 2 cm above. Normal score: <0.50; mild oesophagitis score: ≥0.50 and <1.00; severe oesophagitis score: ≥1.00.
* One patient in the LARS group and two in the ESO group were excluded from the analysis because of incomplete biopsy sampling. † Three patients in the LARS group and one in the ESO group were excluded from the analysis because of incomplete biopsy sampling.
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